Zymeworks Inc
NYSE:ZYME
Zymeworks Inc
Revenue
Zymeworks Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Zymeworks Inc
NYSE:ZYME
|
Revenue
$76m
|
CAGR 3-Years
25%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Revenue
$51.1m
|
CAGR 3-Years
700%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Revenue
$2.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Revenue
$175.5m
|
CAGR 3-Years
52%
|
CAGR 5-Years
223%
|
CAGR 10-Years
68%
|
|
Spectral Medical Inc
TSX:EDT
|
Revenue
CA$1.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-5%
|
|
Sunshine Biopharma Inc
OTC:SBFM
|
Revenue
$24.1m
|
CAGR 3-Years
601%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Zymeworks Inc's Revenue?
Revenue
76m
USD
Based on the financial report for Dec 31, 2023, Zymeworks Inc's Revenue amounts to 76m USD.
What is Zymeworks Inc's Revenue growth rate?
Revenue CAGR 5Y
7%
Over the last year, the Revenue growth was -82%. The average annual Revenue growth rates for Zymeworks Inc have been 25% over the past three years , 7% over the past five years .